(Nasdaq: IMNN) Targets A Forecasted $7.82Bn Market For Disruption (Tight Float Under 4Mn Shares)

Thirty years. That is how long women

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored (Nasdaq: IMNN) Targets A Forecasted $7.82Bn Market For Disruption (Tight Float Under 4Mn Shares) *Get Our Updates Faster—Tap Here To Receive SMS Alerts* July 21st Greetings, Friend! Thirty years. That is how long women diagnosed with newly diagnosed advanced ovarian cancer have faced the same fundamental treatment: platinum-based chemotherapy. No immunotherapy, not a single one, had ever convincingly moved the needle on overall survival in this exact frontline setting. Then came Imunon, Inc. (Nasdaq: IMNN). Based in Lawrenceville, New Jersey, Imunon is a clinical-stage biopharmaceutical company developing what it believes is the first IL-12 immunotherapy capable of delivering meaningful survival benefits in frontline advanced ovarian cancer, without the systemic toxicities that derailed earlier IL-12 attempts. The company’s lead program, IMNN-001, uses a proprietary nanoparticle delivery platform to activate the immune system directly inside the tumor, where it counts. The Phase 2 data told a compelling story. In a randomized 112-patient OVATION 2 study, IMNN-001 added a median of 14.7 months to overall survival compared to standard-of-care chemotherapy alone, a 45.1-month median versus 30.4 months in the control arm. In the subgroup of patients who also received PARP inhibitor maintenance therapy, that survival advantage expanded to 24.2 months. The OVATION 2 data was subsequently published in the peer-reviewed journal Gynecologic Oncology and selected for an oral presentation at the 2025 ASCO Annual Meeting, one of oncology’s most competitive scientific forums. Now the company is running OVATION 3, a 500-patient, randomized, Phase 3 registrational trial with overall survival as its primary endpoint. The first patient was dosed in Q3 2025. Enrollment is currently ahead of schedule, with 50% enrollment now targeted by Q1 2028, roughly a year ahead of the original plan. Two planned interim analyses give the program structural flexibility to potentially stop early for efficacy if the data warrants it. Then came June 2026. On June 23rd, an independent Data Monitoring Committee reviewed the OVATION 3 safety data and recommended the trial continue without modification. That same month, Imunon secured up to $10Mn in structured, non-dilutive financing to advance the Phase 3 program. With approximately 3.63Mn shares in the public float, IMNN is a name with a tight share structure at a moment when its clinical narrative is building real momentum. ABOUT IMUNON, INC. (Nasdaq: IMNN) Imunon was built from the former clinical-stage company Celsion Corporation, which rebranded in 2022 to reflect its concentrated focus on DNA-based immunotherapy. At the heart of that focus is the proprietary TheraPlas® platform, a non-viral, nanoparticle delivery system designed to transport therapeutic DNA directly into the tumor microenvironment without the manufacturing challenges or immunogenic risks tied to viral vector approaches. IMNN-001 is a DNA plasmid encoding interleukin-12 (IL-12), a potent immune-activating cytokine, delivered intraperitoneally (directly into the abdominal cavity). Earlier attempts to harness IL-12 systemically failed because the doses needed for therapeutic effect caused severe toxicity. Imunon’s approach sidesteps that entirely. By delivering IL-12 locally through TheraPlas®, the company’s treatment activates the immune system at the tumor site, converting an immunologically “cold” tumor into an active, immune-engaged environment, while keeping systemic exposure to a minimum. In OVATION 2, zero serious immune-related adverse events were observed. The pipeline extends well beyond ovarian cancer. The same TheraPlas® platform is being positioned for colorectal cancer, pancreatic cancer, and glioblastoma. IMNN-001 holds FDA Fast Track designation and Orphan Drug designation in both the United States and the European Union, a regulatory package that may support an accelerated path toward a potential BLA submission. Product Pipeline of DNA-based Transformative Medicines Market Sector Analysis The ovarian cancer therapeutics market is not a niche. According to Fortune Business Insights, the global market was valued at $4.36Bn in 2025 and is projected to reach $7.82Bn by 2034, growing at a compound annual rate of 6.71%. North America accounts for $1.58Bn of that market and represents the most advanced treatment landscape globally. PARP inhibitors have extended progression-free survival in biomarker-defined subgroups. Checkpoint inhibitors have shown mixed results across solid tumor indications. But no immunotherapy has yet proven a statistically significant improvement in overall survival in the frontline, newly diagnosed advanced ovarian cancer setting. This is the precise indication Imunon is pursuing in OVATION 3. That creates an analytically notable gap in the treatment landscape, and it is the gap IMNN-001 is positioned to address. With an estimated 20,000 new U.S. cases and 300,000 cases worldwide annually, with over 70% diagnosed at advanced stage, exactly the setting IMNN-001 targets. [Market data source] 7 Potential Catalysts Putting (Nasdaq: IMNN) At The Top Of Our Watchlist #1. Independent Safety Panel Clears Phase 3 Trial Without a Single Modification: In June 2026, an independent Data Monitoring Committee reviewed OVATION 3 safety data and recommended IMNN continue its Phase 3 trial exactly as designed, a direct external validation that the program’s safety profile and trial design are holding up under formal scrutiny. #2. Phase 3 Enrollment Running a Full Year Ahead of the Original Timeline: The OVATION 3 trial is enrolling faster than originally projected, with IMNN now targeting 50% enrollment by Q1 2028, a pace that has the potential to pull forward interim analysis timelines and bring the program to pivotal data readouts sooner than the original plan anticipated. #3. A 14.7-Month Overall Survival Benefit With No Comparable Frontline Rival: No other approved frontline therapy in newly diagnosed advanced ovarian cancer has reported a median overall survival benefit comparable to what IMNN produced in its randomized Phase 2 trial, a clinical data point that anchors the entire rationale for the ongoing Phase 3 registrational program. #4. MD Anderson MRD Data Points to Deeper, More Durable Response Signals: Preliminary minimal residual disease data from researchers at MD Anderson Cancer Center showed a 100% no-evidence-of-disease rate at second-look surgery in the treatment arm versus 56% in control, an early-stage data point that adds another clinical dimension to the picture being built around IMNN and its mechanism of action. #5. A Public Float of Approximately 3.63Mn Shares Commands Attention: Market watchers tend to track share structure carefully, and with roughly 3.63Mn shares in the public float, IMNN carries one of the more restrained structures in the clinical-stage biotech space, a data point worth noting as Phase 3 milestones approach. #6. Non-Dilutive $10Mn Financing Keeps the Phase 3 Program Fully Funded: A structured financing package of up to $10M, secured in June 2026 on a non-dilutive basis, provides IMNN with a capital framework designed to advance OVATION 3 without the share dilution that commonly weighs on small-cap biotech programs at critical clinical junctures. #7. A Proprietary Platform Positioned Across Multiple Hard-to-Treat Cancers: The TheraPlas® technology powering IMNN’s lead ovarian cancer program is already being advanced toward colorectal cancer, pancreatic cancer, and glioblastoma, three indications that represent some of the deepest unmet needs in oncology, and a pipeline that extends the platform’s reach well beyond the current Phase 3 registration program. Closing Thoughts Imunon, Inc. (Nasdaq: IMNN) is not a company chasing yesterday’s science. It is a team that identified a 30-year stall in frontline ovarian cancer care, and built a technology platform specifically engineered to address it. The clinical evidence from OVATION 2 was presented at ASCO, published in a peer-reviewed journal, and is now the foundation for a 500-patient Phase 3 registrational trial enrolling ahead of schedule. An independent safety panel has cleared the path forward. The FDA has aligned on the trial protocol and confirmed the route to a potential BLA filing. Non-dilutive capital is in place. Fast Track and Orphan Drug designations are secured in both the United States and European Union. For a company with approximately 3.63Mn shares in the public float and a market cap of roughly $7.5Mn (7/20/26), the clinical and regulatory scaffolding around IMNN is worth understanding carefully. We're initiating coverage on Imunon, Inc. (Nasdaq: IMNN). Be on the lookout for updates heading your way soon. Talk again shortly. All the best, Dane James Editor Market Pulse Today More Sources: IMNN Website (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 07/20/2026 and ending on 07/21/2026 to publicly disseminate information about (IMNN:US) via digital communications. Under this agreement, TD Media LLC has paid Thousand Sun Media LLC seven thousand five hundred USD ("Funds"). These Funds were part of the twenty five thousand USD funds that TD Media LLC received from a third party named LFG Equities Corp. who did not receive the Funds directly or indirectly from the Issuer and does not own st-ock in the Issuer but the reader should assume that the clients of the third party own shares in the Issuer, which they will liquidate at or near the time you receive this communication and has the potential to hurt share prices. Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (IMNN:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/imnn-anfzj/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice